View Older Stories View More Recent Stories
-
Hemostemix CEO Introduces Conformal Consciousness Hypothesis A = E/(hv)
-
Hemostemix Grants Stock Options
-
Hemostemix Inc. Announces FDA Pre-IND Meeting and NBPP of $960,000
-
Hemostemix appoints Shaune Harding as director of patient care
-
Hemostemix Welcomes Shaune Harding, OStJ, RN as Director of Patient Care & Clinical Operations
-
Hemostemix Featured at Innovations in Wound Healing 2025, Key West, December 11-14
-
Hemostemix closes $518,440 private placement, to attend DFCon
-
Hemostemix to Attend DFCon San Antonio and Closed its Private Placement
-
Hemostemix Starts its Roll-up of Cardiology Practices, Acquiring its First Two
-
Dr. William R. Shankle to Advance ACP-01 as a Treatment for Vascular Dementia
-
Hemostemix closes CDN$280,594 private placement
-
Hemostemix Closes CDN$280,594 Private Placement
-
Hemostemix to Showcase Breakthrough Wound Healing Therapy at Innovations in Wound Care Conference Florida
-
Hemostemix Presents ACP-01 Data at University of Florida Grand Rounds: Highlights Strong Safety, Functional Gains, and Florida Access Pathway
-
Hemostemix raises $461,230 in private placement financing
-
Hemostemix Closes Private Placement of $461,230
-
Hemostemix's Boots on the Ground in Florida October Update
-
Hemostemix Announces Its Webinar for Florida Vascular Surgeons: Autologous Stem Cell Therapy for CLTI
-
Hemostemix Granted Trademark "KNOW YOUR HEALTH" in Japan, International Registration No. 1744775 Covers Stem Cell Preparations and Research in Classes 1, 5, 42
-
Hemostemix adds refractory angina treatment to phase 1 clinical trial
-
Hemostemix Adds the Treatment of Refractory Angina to Its Phase 1 Basket Protocol
-
Hemostemix Files for Ethics Approval of its Study of Vascular Dementia
-
Hemostemix receives $330,000 lead order for private placement
-
Hemostemix's Insider Lead Order of $330,000 Private Placement
-
Hemostemix files FDA pre-submission for multi-indication stem cell trial
-
Hemostemix Files FDA Submission for Basket Protocol (Filing 1517) to Advance ACP-01 (VesCell(TM)) Across Multiple Ischemic and Vascular Indications Simultaneously
-
Hemostemix to Present at Life Science Investor Forum
-
Hemostemix to Present Its Clinical Data of the Treatment of Severe Angina
-
Hemostemix Announces TSXV Approval of Debt Settlement at $0.20 per Share
-
Hemostemix raises $280,594 in private placement at $0.125 per share
-
Hemostemix Announces Private Placement
-
Hemostemix Launches Enhanced HubSpot-Powered Websites to Support Global Marketing & Sales of ACP-01 for No-Option Patients
-
Hemostemix's VesCell.Health Launched in Florida
-
Howie's 17+ Years After VesCell(TM): Following Hemostemix's Heart Patients
-
Hemostemix Announces Financing Plans for VesCell(TM) Treatment
-
Hemostemix's Boots on the Ground in Florida
-
Hemostemix's Social Media for Investors and Florida's No-Option Patients
-
Hemostemix Announces Its AI Strategy
-
Hemostemix's Expands its Marketing Team Focused on Sales in Florida
-
Hemostemix Contracts Empire Market Ventures to Increase Market Awareness
-
Hemostemix increases private placement to $3 million
-
Hemostemix Increases Previously Closed Private Placement to $3,000,000
-
Cells: Hemostemix ACP-01 Provides the Scientific Basis for Improving the Longevity and Signal Uptake of Brain Computer Implants
-
Hemostemix Closes $2,969,600 Private Placement
-
Hemostemix Closes Sale of 23rd ACP-01 Therapy Convertible Debenture
-
Hemostemix Closing $3,000,000 Private Placement
-
Hemostemix Oversubscribed, Closing $2,700,000 Private Placement and Settles $400,000 of Debt at $0.20 per Share
-
Hemostemix Closes $469,366 Private Placement
-
Hemostemix Announces its 10th Publication: A Molecular Strategy for the Treatment of Heart Failure: Response to BioCardia's Cardiamp Heart Failure Trial
-
Hemostemix's VesCell Sales are Legal in Florida as it Pivots to Allow Non-FDA Approved Stem Cell Treatments!
